Pharmacologic inhibition of Sirtuin-2 (Sirt2), a NAD+-dependent deacetylase inhibiting T-cell metabolism and impairing T-cell effector functions, endows human tumor-infiltrating lymphocytes (TILs) with superior metabolic fitness and effector functions [174]. This evidence concerns the gene SIRT2 and neoplasm.